ONCY pelareorep selected for Phase 3 Pancreatic Cancer trialThis is a significant development. PanCAN created the Precision Promise adaptive clinical trial because traditional clinical trial designs are slow to evaluate new treatment options for pancreatic cancer patients. PanCAN’s novel clinical trial platform is designed to more efficiently test new therapies for their effectiveness in treating patients with pancreatic cancer by requiring fewer patients to understand if a potential new therapy is working. The platform is also designed to allow multiple investigational therapies to be tested simultaneously.
https://pancan.org/research/precision-promise/
PanCAN’s Precision Promise Clinical Trial Consortium of over 20 clinical sites were selected through a competitive, peer-review process and include premier cancer treatment institutions across the country.
https://pancan.org/research/precision-promise/locations/